<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11556">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956499</url>
  </required_header>
  <id_info>
    <org_study_id>APX001-101</org_study_id>
    <nct_id>NCT02956499</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of APX001 Administered Intravenously</brief_title>
  <official_title>A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amplyx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amplyx Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose
      (SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects. The
      SAD portion of the study will enroll six cohorts of eight healthy subjects per cohort, for a
      total of approximately 48 healthy subjects. The MAD portion of the study will enroll four
      cohorts of eight healthy subjects per cohort, for a total of approximately 32 healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and multiple doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG).</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by area under the curve (AUC).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by terminal phase half-life (t1/2).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel).</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of single and multiple dose of APX001 as measured by accumulation ratio.</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple intravenous doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple intravenous doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple intravenous doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple intravenous doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single dose 1</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single dose 2</intervention_name>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single dose 3</intervention_name>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single dose 4</intervention_name>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single dose 5</intervention_name>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 single dose 6</intervention_name>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple dose 1</intervention_name>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple dose 2</intervention_name>
    <arm_group_label>Cohort 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple dose 3</intervention_name>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APX001 multiple dose 4</intervention_name>
    <arm_group_label>Cohort 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_label>Cohort 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of childbearing potential must agree to avoid pregnancy during the study and to
             use contraception at least 2 weeks before the start of the study until 3 months after
             the last dose of study drug.

          -  Males with partner(s) of childbearing potential must agree to use appropriate barrier
             contraception from the screening period until 3 months after the last dose of study
             drug.

          -  Screening hematology, clinical chemistry, coagulation and urinalysis consistent with
             overall good health.

          -  No significantly abnormal findings on physical examination, ECG and vital signs.

          -  Willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Any uncontrolled or active major systemic disease including, but not limited to:
             cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological,
             immunological, psychiatric, or neoplastic disorder with metastatic potential.

          -  History or presence of malignancy within the past year. Subjects who have been
             successfully treated with no recurrence of basal cell carcinoma of the skin or
             carcinoma in-situ of the cervix may be enrolled.

          -  Use of prescription medication within 14 days prior to the first dose of study drug
             and throughout the study.

          -  Use of non-prescription or over-the-counter medications within 7 days prior to the
             first dose of study drug and throughout the study.

          -  Positive results on any of the following Screening laboratory tests: serum pregnancy
             test, urine alcohol test, urine drugs of abuse, hepatitis B surface antigen,
             hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Hodges, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amplyx Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela C Wedel</last_name>
    <email>pwedel@amplyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PRA Health Sciences</last_name>
      <phone>0031-50-8505798</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>November 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
